The WIRB-Copernicus Group’s (WCG) Clinical Services Division yesterday announced its partnership with Inspire, which has 1.5m members and 10m active annual users across 225 individual communities representing more than 3,600 discrete medical conditions. The news comes on the heels of a partnership with InformedDNA to support clinical trials using genetics.
“WCG and Inspire both recognize the critical role that patients play in advancing medical progress,” said Donald A. Deieso, PhD, executive chairman and chief executive officer, WCG.
Through its partnership with Inspire, Deieso said it is “making it easier for patients to access cutting-edge treatments by helping them identify relevant clinical trial opportunities.” Additionally, he noted that it also will make it easier for researchers to locate hard-to-find patients interested in participating in research.
“By adding Inspire to WCG’s already robust patient engagement platform, we’re enabling research sponsors to connect directly and more effectively with potential research volunteers, making clinical trials more patient-centric and ultimately accelerating the development of life-changing therapies to the patients who need them,” Deieso told us.
The companies will use permission-based and opt-in approaches to connect patients with clinical trial opportunities. As the Inspire network grows – membership to which is open to patients, caregivers, and providers across all therapeutic areas – Dieso said the company has an opportunity to serve each community, among new ones.
“WCG has a number of resources to share with Inspire community members, including the guidance of genetic specialists and counselors through our partnership with InformedDNA,” he said. “WCG and Inspire are committed to empowering patients by giving them greater access to educational resources and clinical trial opportunities.”